ATE481971T1 - Formulierung von 3-amino-8-(1-piperazinyl)-2h- 1benzopyran-2-on mit verzögerter freisetzung - Google Patents

Formulierung von 3-amino-8-(1-piperazinyl)-2h- 1benzopyran-2-on mit verzögerter freisetzung

Info

Publication number
ATE481971T1
ATE481971T1 AT05761109T AT05761109T ATE481971T1 AT E481971 T1 ATE481971 T1 AT E481971T1 AT 05761109 T AT05761109 T AT 05761109T AT 05761109 T AT05761109 T AT 05761109T AT E481971 T1 ATE481971 T1 AT E481971T1
Authority
AT
Austria
Prior art keywords
piperazinyl
amino
release formulation
sustained release
disorders
Prior art date
Application number
AT05761109T
Other languages
English (en)
Inventor
Nico Bruins
Henderik W Frijlink
Vries Michiel H De
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Application granted granted Critical
Publication of ATE481971T1 publication Critical patent/ATE481971T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
AT05761109T 2004-07-15 2005-07-13 Formulierung von 3-amino-8-(1-piperazinyl)-2h- 1benzopyran-2-on mit verzögerter freisetzung ATE481971T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58803604P 2004-07-15 2004-07-15
EP04103378 2004-07-15
PCT/EP2005/053341 WO2006005760A1 (en) 2004-07-15 2005-07-13 Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one

Publications (1)

Publication Number Publication Date
ATE481971T1 true ATE481971T1 (de) 2010-10-15

Family

ID=34978928

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05761109T ATE481971T1 (de) 2004-07-15 2005-07-13 Formulierung von 3-amino-8-(1-piperazinyl)-2h- 1benzopyran-2-on mit verzögerter freisetzung

Country Status (8)

Country Link
EP (1) EP1781292B1 (de)
JP (1) JP2008506668A (de)
AT (1) ATE481971T1 (de)
CA (1) CA2570096A1 (de)
DE (1) DE602005023742D1 (de)
PL (1) PL1781292T3 (de)
PT (1) PT1781292E (de)
WO (1) WO2006005760A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2468264A1 (de) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Orale pharmazeutische Tablette zur gesteuerten Abgabe von Mesalazin und Verfahren zu deren Erhalt
GB201504986D0 (en) * 2015-02-13 2015-05-06 Johnson Matthey Plc Oxidation catalyst for treating a natural gas emission
JP6983139B2 (ja) * 2017-11-27 2021-12-17 信越化学工業株式会社 固形製剤用組成物並びに固形製剤及びその製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650964A1 (de) * 1993-11-02 1995-05-03 Duphar International Research B.V 1- 2H-1-Benzopyran-2-on-8-yl -Piperazin Derivate
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
NL9401572A (nl) * 1994-09-27 1996-05-01 Avebe Coop Verkoop Prod Zetmeelprodukten als tabletteerhulpstof, werkwijze voor het bereiden daarvan alsmede werkwijze voor het maken van tabletten.
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US6312717B1 (en) * 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression

Also Published As

Publication number Publication date
PT1781292E (pt) 2010-12-23
CA2570096A1 (en) 2006-01-19
PL1781292T3 (pl) 2011-03-31
EP1781292B1 (de) 2010-09-22
WO2006005760A1 (en) 2006-01-19
DE602005023742D1 (de) 2010-11-04
JP2008506668A (ja) 2008-03-06
EP1781292A1 (de) 2007-05-09

Similar Documents

Publication Publication Date Title
EA202091303A2 (ru) Композиция ингибитора jak для местного применения
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
DOP2002000429A (es) Imidazotriazinas
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
TNSN07376A1 (en) Npy antagonists, preparation and use
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
SG146657A1 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
ATE453642T1 (de) Substituierte phenylaminopyrimidine
MY142329A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
ATE448232T1 (de) Substituierte heterozyklen
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
ATE481971T1 (de) Formulierung von 3-amino-8-(1-piperazinyl)-2h- 1benzopyran-2-on mit verzögerter freisetzung
EP2323656A4 (de) Pharmazeutisches produkt mit einem muscarinrezeptorantagonist und einem beta-2-adrenozeptoragonist

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1781292

Country of ref document: EP